Assuntos
Corticosteroides/uso terapêutico , Antifúngicos/uso terapêutico , Dermatite Seborreica/terapia , Inibidores Enzimáticos/uso terapêutico , Ceratolíticos/uso terapêutico , Fototerapia , Administração Cutânea , Lesões Encefálicas Traumáticas/epidemiologia , Inibidores de Calcineurina , Dermatite Seborreica/epidemiologia , Dermatite Seborreica/imunologia , Dermatomicoses/epidemiologia , Dieta , Dermatoses Faciais , Humanos , Imidazóis/uso terapêutico , Malassezia , Compostos Organometálicos/uso terapêutico , Doença de Parkinson/epidemiologia , Piridinas/uso terapêutico , Fatores de Risco , Dermatoses do Couro Cabeludo , Compostos de Selênio/uso terapêutico , Traumatismos da Medula Espinal/epidemiologiaRESUMO
Relatively molecular mass of GnRH antigens is small and hence needs to couple to a large carrier molecule to enhance its immunogenicity. This study investigated whether hepatitis B surface antigen S (HBsAg-S) gene can be used as an effective carrier molecule for developing GnRH DNA immunocastration vaccine. Two copies of human GnRH gene were fused with HBsAg-S gene for constructing a recombinant plasmid pVAX-HBsAg-S-2GnRH that coded for 27 kDa target fusion protein. Ten male mice were divided into two equal groups, treatment and control. The vaccine (50 µg/mice) prepared in saline solution was injected into male mice at weeks 0, 1, 2, 4 and 7 of the experiment. Vaccine's efficacy was evaluated in terms of GnRH-specific IgG antibody response, plasma testosterone levels, testicular weight and extent of the testicular tissue damage. The specific anti-GnRH antibody titre in vaccinated animals was significantly higher than in controls in only 4th week of immunization (p < 0.05). In addition, vaccinated animals showed lower testicular weight than those of the controls (p < 0.05). Spermatogenesis in seminiferous tubules in vaccinated animals was suppressed. In conclusion, in this study, the engineered plasmid to be used as a GnRH DNA vaccine induced antibody response and suppressed spermatogenesis in mice. This suggests that HBsAg-S gene can be an effective carrier molecule for developing GnRH DNA immunocastration vaccine when relatively molecular mass of the aimed antigens is small.